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Study Objective. To evaluate risk factors for the development of arthralgias
or myalgias associated with quinupristin-dalfopristin.
Design. Retrospective chart review and case-control analysis.
Setting. An 850-bed tertiary care medical center.
Patients. All adult and pediatric patients who had received quinupristin-
dalfopristin through either a compassionate-use protocol (February
1996–October 1999) or in the year after quinupristin-dalfopristin was
added to the hospital formulary (November 1999–October 2000) were
included in this study.  Case patients were those who developed arthralgias
or myalgias while receiving quinupristin-dalfopristin therapy; control
patients were those who received quinupristin-dalfopristin but did not
develop arthralgias or myalgias.
Intervention. Medical records, pharmacy dispensing information, and
microbiology data were reviewed by a physician and a pharmacist, both of
whom specialized in infectious diseases.  Presence or absence of arthralgias
or myalgias was the primary outcome assessed.
Measurements and Main Results. Quinupristin-dalfopristin was
administered to 68 patients during the period defined by the study.
Arthralgias and myalgias could not be assessed in 18 of the 68 patients
because they were sedated and paralyzed, or they were young children who
could not communicate the presence of pain.  Univariate analysis
demonstrated that significant risk factors for arthralgias or myalgias
associated with quinupristin-dalfopristin were female sex, chronic liver
disease, receipt of liver transplant, elevated bilirubin level at baseline, major
surgery, and receipt of either mycophenolate or cyclosporine.  Multivariate
analysis demonstrated a strong association with chronic liver disease,
receipt of liver transplant, elevated bilirubin level at baseline, and receipt of
either cyclosporine or mycophenolate.  Of 50 evaluable patients receiving
quinupristin-dalfopristin, 25 had pain that may have been associated with
this antimicrobial agent.
Conclusion. The mechanism for development of arthralgias or myalgias
associated with quinupristin-dalfopristin remains unknown, but these
adverse events are more likely to occur in patients with chronic liver
disease and those who have received a liver transplant or are receiving
cyclosporine or mycophenolate.
(Pharmacotherapy 2003;23(2):159–164)
Quinupristin-dalfopristin is a streptogramin
agent with a broad spectrum of activity against
many resistant gram-positive organisms, such as
vancomycin-resistant Enterococcus faecium and
methicillin-resistant Staphylococcus aureus.1–3
During initial treatment trials with quinupristin-
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dalfopristin, arthralgias or myalgias were not
reported in some studies4, 5 and were reported in
approximately 10% of patients in others.6–8
However, several subsequent reports demon-
strated a rate of occurrence of these adverse
effects of 33–47%.9–11
In our medical center it appeared that a
significant proportion of patients receiving
quinupristin-dalfopristin experienced arthralgias
or myalgias, and often required therapy with
intravenous analgesics or discontinuation of
quinupristin-dalfopristin.  We reviewed our
experience to assess the proportion of patients
who developed these adverse effects and to
determine if specific underlying illnesses or
concurrent drugs contributed to their occurrence.
Methods
Setting and Patients
The University of Michigan Hospitals and
Health Centers comprise an 850-bed tertiary care
center with solid organ and bone marrow
transplant services.  All adult and pediatric
patients who had received quinupristin-
dalfopristin either through a compassionate-use
protocol (February 1996–October 1999) or in the
year after quinupristin-dalfopristin was added to
the hospital formulary (November 1999–October
2000) were included in our study.  Case patients
were those who developed arthralgias or myalgias
while receiving quinupristin-dalfopristin; control
patients were those who received quinupristin-
dalfopristin but did not develop arthralgias or
myalgias.  Only patients with complete medical
records were assessed.  Approval from the
institutional review board was obtained for this
retrospective chart review.
Data Collection
Medical records, pharmacy dispensing
information, and microbiology data were
reviewed.  The dates, dosages, and durations of
quinupristin-dalfopristin therapy were noted.
Relevant clinical information, concomitant drugs,
and laboratory data were recorded.  Medical
conditions of particular interest were chronic
liver or kidney disease, hematologic malignancies,
receipt of a solid organ or bone marrow
transplant, dialysis, hospital stay in intensive care
unit, mechanical ventilation, and recent surgery.
Concurrent drugs were reviewed for potential
drug interactions.  Dosages of concurrent drugs
metabolized by cytochrome P450 (CYP) 3A4
were recorded.
Charts were reviewed by a physician and a
pharmacist, both of whom specialized in
infectious diseases.  Presence or absence of
arthralgias or myalgias was the primary outcome
assessed.  Presence of pain was ascertained from
progress notes of medical and nursing staff;
patients had to have communicated to health
care personnel that they experienced muscle or
joint pain.  Arthralgias or myalgias were
considered associated with quinupristin-
dalfopristin if they were temporally related to
quinupristin-dalfopristin therapy and no other
cause was identified.
Statistical Analysis
Potential risk factors for arthralgias or myalgias
during quinupristin-dalfopristin therapy were
identified by means of univariate analysis.  Either
the x2 or the two-tailed Fisher’s exact test was
used for categorical variables.  Continuous
variables were compared using the Student t test
or the Mann-Whitney U test.  Variables that were
significant in the univariate analysis were further
tested by logistic regression using the forward
conditional method; a p value less than 0.05 was
considered statistically significant.  Statistical
analysis was performed using SAS 6.0 and
Statview 5.0.1 (SAS Institute, Cary, NC).
Results
Complete medical records were available for 68
patients; of those, the occurrence of arthralgias
and myalgias could not be assessed in 18 (26.5%)
because the patients were intubated, sedated, and
paralyzed, or they were young children who
could not communicate the presence of pain.
Mean age of the 50 evaluable patients was 48.4 ±
14.4 years; only two were younger than 18 years.
Two children received quinupristin-dalfopristin;
one, an infant, was treated on three separate
occasions, for a total of 57 days of therapy.
Because he was only 3 months old at the start of
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therapy, it was impossible to discern whether he
experienced arthralgias or myalgias during
therapy.  The second child received quinupristin-
dalfopristin for 20 days.  Although 5 years old,
this child was noncommunicative.  Thus, both
pediatric patients were placed in the unassessable
group.
Twenty-five (50%) of the 50 patients experienced
arthralgias or myalgias.  We could not determine
from the medical records of most patients
whether the symptoms were primarily muscular
or articular; complaints were generally of diffuse
aching and pain that was not localized to joints
or muscle groups.  All patients were given
quinupristin-dalfopristin 7.5 mg/kg as an
intravenous infusion every 8 hours.  The dosage
for two adult patients was decreased later to 5
mg/kg every 8 hours in an effort to reduce their
arthralgias and myalgias.
Onset of symptoms occurred an average of 3.1
± 2 days (range 1–5 days) after therapy was
started.  For the 13 patients who completed
therapy despite having arthralgias or myalgias,
these symptoms resolved a mean of 4.2 ± 2 days
after quinupristin-dalfopristin was stopped.
Symptoms improved in the two patients whose
quinupristin-dalfopristin dosage had been
decreased, and two patients refused further
infusions because of the severity of their
symptoms.  Of the 25 patients who developed
arthralgias or myalgias, 12 died as a result of
underlying disease processes; of the 25 who had
no arthralgias or myalgias, nine died.
Univariate analysis showed the following
significant risk factors for arthralgias or myalgias
associated with quinupristin-dalfopristin:  female
sex, chronic liver disease, receipt of liver
transplant, major surgery, elevated bilirubin level
at baseline, and receipt of either mycophenolate
and cyclosporine (Table 1).  A multivariate
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Table 1.  Univariate Analysis Results of Patients with and without Arthralgias or Myalgias Associated with Quinupristin-
Dalfopristin Therapy
No. of Patients No. of Patients
with Arthralgias without Arthralgias
or Myalgias or Myalgias Odds Ratio
Variable (n=25) (n=25) p Value (95% confidence interval)
Age, yrs (mean ± SD) 49.3 ± 13.7 47.4 ± 15.3 0.71 2.1 (0.6–9.5)
M/F 10/15 17/8 0.047 3.2 (1.0–10.1)
Duration of quinupristin-dalfopristin
therapy, days (mean ± SD) 15.9 ± 10.8 12.8 ± 14.2 0.57 1.8 (0.5–6.8)
Medical history
Chronic liver disease 13 4 0.01 7.9 (1.8–35.2)
Liver transplantation 9 2 0.02 6.5 (1.2–34.0)
Other major surgery 19 10 0.01 4.8 (1.4–16.1)
Chronic renal failure 10 8 0.56 1.4 (0.4–4.5)
Dialysis 13 9 0.25 1.9 (0.6–6.0)
Bone marrow transplantation 3 7 0.16 0.4 (0.1–1.6)
Hematologic malignancy 5 9 0.21 0.4 (0.1–1.6)
Had hospital stay in intensive care unit 15 9 0.09 2.7 (1.9–8.4)
Elevated levels at baseline
Aspartate and alanine aminotransferases 6 2 0.07 4.6 (0.8–26.5)
Alkaline phosphatase 5 4 0.06 1.5 (0.3–6.3)
Bilirubin 12 5 0.03 3.7 (1.0–13.0)
Elevated levels during therapy
Aspartate and alanine aminotransferases 6 2 0.07 2.6 (1.7–9.3)
Alkaline phosphatase 9 3 0.35 2.1 (0.4–9.9)
Bilirubin 14 10 0.23 2.1 (0.6–7.0)
Mechanical ventilation required 12 9 0.39 1.6 (0.5–5.1)
Concomitant drug therapy
Mycophenolate 10 3 0.04 4.4 (1.0–18.6)
Cyclosporine 10 4 0.05 3.5 (1.9–13.3)
Tacrolimus 5 6 0.73 0.8 (0.2–3.0)
Fluconazole 15 13 0.57 1.4 (0.5–4.3)
Omeprazole 11 9 0.56 1.4 (0.5–4.4)
Corticosteroids 14 10 0.26 1.9 (0.6–5.9)
Conjugated estrogens 5 3 0.44 1.8 (0.4–8.7)
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logistic regression model demonstrated that
chronic liver disease, receipt of liver transplant,
elevated bilirubin level at baseline, and receipt of
either mycophenolate or cyclosporine remained
independently associated with development of
myalgias and arthralgias during quinupristin-
dalfopristin therapy (Table 2).
Discussion
Quinupristin is converted to two conjugated
metabolites and dalfopristin to one nonconju-
gated metabolite.2 We were concerned that some
patients could exhibit higher plasma concen-
trations of quinupristin, dalfopristin, or their
metabolites.  Because the frequency of arthralgias
and myalgias may be higher in these patient
populations, we felt it important to look for this
possible association.  Although single-dose (7.5
mg/kg) studies12 suggest that age, sex, and
obesity appear to have no clinically significant
effects on the pharmacokinetics of quinupristin-
dalfopristin, limited pharmacokinetic data
suggest that plasma concentrations of quinupristin
and dalfopristin may be slightly impaired in
patients with severe chronic renal failure.12
However, no accumulation of the parent drugs or
their metabolites was evident in patients with
end-stage renal disease who received an infusion
of quinupristin-dalfopristin 7.5 mg/kg twice/day.
In patients with cirrhosis, mean values for area
under the curve (AUC) of quinupristin and
dalfopristin in combination with their respective
metabolites were approximately 2.8 and 1.5 times
higher than in healthy volunteers.  Also, patients
with high bilirubin levels (> 3 times normal)
have experienced a marked increase in exposure
to quinupristin metabolites (up to a 4-fold
increase in AUC) because of delayed elimination
of the drug.12
Quinupristin-dalfopristin does not significantly
inhibit the human CYP isoenzymes 1A2, 2A6,
2C9, 2C19, 2D6, or 2E1.12 However, although
quinupristin-dalfopristin is not metabolized by
CYP3A4, it inhibits the biotransformation rate of
specific CYP3A4 substrates, such as nifedipine,
midazolam, terfenadine, and cyclosporine.  Thus,
concurrent drugs chosen for evaluation in this
study were primarily known or suspected
substrates, inhibitors, and inducers of this
enzyme.
We also evaluated drugs such as digoxin that
are substrates, inhibitors, or inducers of P-
glycoprotein, and commonly used agents that
interact (through other CYP pathways) with
numerous drugs.  Of these other agents, the most
commonly administered were digoxin and
omeprazole.  Administration of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors
was monitored specifically because of their
metabolism by the CYP pathway and the
arthralgias and myalgias observed with elevated
plasma concentrations of these agents.  No
patients in our study received these agents.
Myalgias or arthralgias were significant adverse
events among patients receiving quinupristin-
dalfopristin at our medical center.  The 50%
occurrence rate is higher than that observed in
other reports, which noted these symptoms in
0–10% of patients receiving quinupristin-
dalfopristin,4–8 but is similar to that noted in
other series.9–11 In one report, 47% of 32 patients
experienced arthralgias or myalgias related to
quinupristin-dalfopristin, and 60% of the group
with these adverse effects had received a liver
transplant, versus 36% of those without
symptoms.9 Perhaps because of the small
number of patients studied, significant risk
factors for development of arthralgias or myalgias
(e.g., chronic liver disease, receipt of liver
transplant, or elevated bilirubin level) could not
be established.
A study with a group of patients similar to our
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Table 2.  Multivariate Analysis Results of Patients with and without Arthralgias or Myalgias Associated with
Quinupristin-Dalfopristin Therapy
No. of Patients No. of Patients
with Arthralgias without Arthralgias
or Myalgias or Myalgias Odds Ratio
Risk Factor (n=25) (n=25) p Value (95% confidence interval)
Chronic liver disease 13 4 0.03 10.4 (3.5–21.2)
Liver transplantation 9 2 0.04 8.8 (1.4–28.4)
Elevated bilirubin level 9 5 0.01 9.6 (3.9–12.3)
at baseline
Mycophenolate 9 2 0.03 3.2 (2.3–41.1)
Cyclosporine 10 4 0.04 3.8 (1.6–14.6)
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population, most of whom had received a liver
transplant, reported a 33% frequency of
arthralgias or myalgias.  The results also showed
that the frequency was dose related and did not
occur in patients who had received a lower
dosage of 5 mg/kg every 8 hours.11 Another
study noted a 36% frequency of arthralgias or
myalgias associated with quinupristin-
dalfopristin in 56 patients with cancer, most of
whom had leukemia.10 None of these studies
assessed the effects of concomitant drugs on
development of arthralgias or myalgias.
The etiology of arthralgias or myalgias related
to quinupristin-dalfopristin remains unknown.
We found a strong association between the
occurrence of arthralgias or myalgias and liver
disease or liver transplantation.  It is tempting to
speculate that these effects could be related to
increased levels of quinupristin-dalfopristin or its
metabolites that accumulate with hepatic
dysfunction.  Decreasing the dosage might
diminish the risk for development of arthralgias
or myalgias.11 Symptoms improved quickly in
the two patients whose dosage was decreased in
our study.
We anticipated that inhibitors or competitors
of the metabolism of quinupristin-dalfopristin or
its metabolites by CYP3A4 might result in
elevated drug concentrations of quinupristin-
dalfopristin or its metabolites.  However, only
two drugs—mycophenolate and cyclosporine—
were associated with arthralgias or myalgias, and
mycophenolate is not metabolized through the
CYP3A4 route.  Mycophenolate is metabolized
completely to mycophenolic acid (the active form
of mycophenolate), which subsequently is
metabolized to mycophenolic acid glucuronide
by hepatic glucuronosyl transferase.13
Although theoretical, competition for
metabolism by hepatic glucuronosyl transferase
could result in altered concentrations of
quinupristin or dalfopristin; however, no data
support such an interaction.  Despite the
similarity in routes of metabolism of cyclosporine
and tacrolimus, we found no association between
tacrolimus therapy and development of
arthralgias or myalgias.  Our data suggest that
inhibition of metabolism by CYP3A4 leading to
accumulation of quinupristin-dalfopristin
metabolites is probably not the primary
mechanism of development of arthralgias or
myalgias.
Physicians’ notes for several of our patients
made no mention of pain, whereas nurses’ notes
clearly reported pain with movement.  In these
instances, the primary team caring for the patient
did not associate the pain noted by the nurses
with quinupristin-dalfopristin.  Caregivers
should be aware that quinupristin-dalfopristin
causes arthralgias and myalgias, and that these
adverse effects appear to be more common in
patients who have underlying hepatic disease or
are receiving cyclosporine or mycophenolate.
Conclusion
Of 50 evaluable patients receiving quinupristin-
dalfopristin, 25 experienced pain that may have
been associated with this antimicrobial agent.
Multivariate and univariate analysis demonstrated
a strong association between pain and quinupristin-
dalfopristin therapy in patients with chronic liver
disease, receipt of a liver transplant, elevated
bilirubin level at baseline, and receipt of either
cyclosporine or mycophenolate.  The mechanism
of development of arthralgias or myalgias
associated with quinupristin-dalfopristin remains
unknown, but these adverse effects are more
likely to occur in patients with chronic liver
disease and those who have undergone liver
transplantation or are receiving cyclosporine or
mycophenolate.
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